Alpha Tau Medical Ltd. (NASDAQ:DRTS) Sees Significant Decline in Short Interest

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) was the recipient of a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 88,100 shares, a decrease of 27.8% from the March 15th total of 122,000 shares. Based on an average daily trading volume, of 89,800 shares, the short-interest ratio is currently 1.0 days. Approximately 0.2% of the company's stock are short sold.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "buy" rating and issued a $9.00 target price on shares of Alpha Tau Medical in a research report on Monday, March 17th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of DRTS. Renaissance Technologies LLC grew its holdings in Alpha Tau Medical by 188.7% in the 4th quarter. Renaissance Technologies LLC now owns 41,000 shares of the company's stock valued at $127,000 after buying an additional 26,800 shares during the last quarter. Northern Trust Corp boosted its position in shares of Alpha Tau Medical by 112.6% in the fourth quarter. Northern Trust Corp now owns 48,666 shares of the company's stock valued at $151,000 after acquiring an additional 25,770 shares during the period. Finally, Levin Capital Strategies L.P. grew its stake in shares of Alpha Tau Medical by 2.3% in the fourth quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company's stock worth $975,000 after acquiring an additional 7,189 shares during the last quarter. Institutional investors and hedge funds own 2.65% of the company's stock.

Alpha Tau Medical Stock Performance

Shares of DRTS traded up $0.02 during trading hours on Wednesday, hitting $2.64. 5,991 shares of the company were exchanged, compared to its average volume of 47,650. The company has a market cap of $185.81 million, a PE ratio of -6.14 and a beta of 0.93. The firm's 50 day moving average is $2.68 and its 200-day moving average is $2.83. Alpha Tau Medical has a 52 week low of $1.75 and a 52 week high of $4.39.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last announced its quarterly earnings results on Wednesday, March 12th. The company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). As a group, equities analysts forecast that Alpha Tau Medical will post -0.45 earnings per share for the current fiscal year.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.